Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been assigned a consensus rating of "Hold" from the nine brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $8.63.

FULC has been the subject of a number of research reports. HC Wainwright reiterated a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th.

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in shares of Fulcrum Therapeutics in the 4th quarter valued at $38,000. China Universal Asset Management Co. Ltd. increased its stake in Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company's stock valued at $43,000 after purchasing an additional 4,701 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Fulcrum Therapeutics in the 3rd quarter worth $59,000. Intech Investment Management LLC bought a new stake in Fulcrum Therapeutics during the 3rd quarter worth approximately $62,000. Finally, Mariner LLC purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $78,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC traded down $0.38 during mid-day trading on Friday, reaching $3.22. The stock had a trading volume of 333,934 shares, compared to its average volume of 459,442. The business has a 50 day simple moving average of $4.11 and a 200 day simple moving average of $4.51. Fulcrum Therapeutics has a twelve month low of $2.86 and a twelve month high of $13.70. The firm has a market capitalization of $173.54 million, a price-to-earnings ratio of -10.32 and a beta of 2.03.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). As a group, sell-side analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.